Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$63.92T
24h Vol:
$4.36B
Dominance:
MSFT:4.92%
Stocklytics Platform
Instrument logo  SANA
Sana Biotechnology, Inc.
SANA
54 / 100
High Growth
$9.27arrow_drop_down0.96%-$0.09

Performance History

Stocklytics logo
Key Stats
Open$9.30
Prev. Close$9.36
EPS-1.46
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.98B
PE Ratio-
LOWHIGH
Day Range9.16
9.55
52 Week Range2.74
12.00
Ratios
P/B Ratio6.90
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-5.11%
EBITDA Margin %-
ROE %-72.00%
EPS-1.46

Score Breakdown

54vs 55. Market Avg.

All Score 54 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

SANAMARKET
Value3340
Quality3240
Ownership3717
Growth7845
Dividends-37
check_circle

Sana Biotechnology, Inc.'s Price growth average in the last 3 years of 8.45% is great compared to market average of 7.16%. This indicates SANA could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$754.74
24H (%)arrow_drop_down0.63%
24H ($)-$4.85
MARKET CAP$724.46B
PRICE$437.62
24H (%)arrow_drop_down0.92%
24H ($)-$4.10
MARKET CAP$414.91B
PRICE$148.01
24H (%)arrow_drop_down0.52%
24H ($)-$0.77
MARKET CAP$361.94B
PRICE$126.33
24H (%)arrow_drop_up0.14%
24H ($)$0.18
MARKET CAP$321.01B

About Sana Biotechnology, Inc. (SANA)

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG299 and SG242 that targets CD19+ cancer cells in patients with non-Hodgkin Lymphoma (NHL), chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia (ALL); SG221 and SG239 for the treatment of multiple myeloma; and SG233, a CD22 CAR for the treatment of NHL, CLL, and ALL. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255, a B cell maturation antigen directed allogeneic CAR T for multiple myeloma; SC45, the PSC-derived pancreatic islet cells for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, Huntington's disease, and other astrocytic diseases. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is based in Seattle, Washington.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Steven D. Harr M.D.
Headquarters
Seattle
Employees
424
Exchange
NASDAQ
add Sana Biotechnology, Inc. to watchlist

Keep an eye on Sana Biotechnology, Inc.

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Sana Biotechnology, Inc.'s (SANA) price per share?

The current price per share for Sana Biotechnology, Inc. (SANA) is $9.27. The stock has seen a price change of -$0.09 recently, indicating a -0.96% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Sana Biotechnology, Inc. (SANA)?

For Sana Biotechnology, Inc. (SANA), the 52-week high is $12, which is 29.45% from the current price. The 52-week low is $2.74, the current price is 237.7% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Sana Biotechnology, Inc. (SANA) a growth stock?

Sana Biotechnology, Inc. (SANA) has shown an average price growth of 8.45% over the past three years. It has received a score of 70 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Sana Biotechnology, Inc. as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Sana Biotechnology, Inc. (SANA) stock price performance year to date (YTD)?

As of the latest data, Sana Biotechnology, Inc. (SANA) has a year-to-date price change of 120.71%. Over the past month, the stock has experienced a price change of 0.1%. Over the last three months, the change has been 46.68%. Over the past six months, the figure is 189.69%.

help
Is Sana Biotechnology, Inc. (SANA) a profitable company?

Sana Biotechnology, Inc. (SANA) has a net income of -$283.26M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$325.8M. Furthermore, the EBITDA is -$302.34M.

help
What is the market capitalization of Sana Biotechnology, Inc. (SANA)?

Sana Biotechnology, Inc. (SANA) has a market capitalization of $1.98B. The average daily trading volume is 1.06M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.